Paper Details

  1. Home
  2. Paper Details

High Rate of Treatment Completion in Program Settings With 12-Dose Weekly Isoniazid and Rifapentine for Latent Mycobacterium tuberculosis Infection.

Author: Bamrah-MorrisSapna, ChorbaTerence, GriffinPhil, HoChristine S, HolcombeJ Mike, HuntGarrett, JerebJohn, LobatoMark N, MarcoAsween, MarksSuzanne, MaseSundari, MoroRuth N, MukasaLeonard, NwanaNwabunie, PatilNaveen, SandulAmy L, ShahNeha, StewartBrock, WangShu-Hua, WebbRisa

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This article discusses the efficacy of a 12-week directly observed isoniazid and rifapentine (3HP) regimen for latent tuberculosis (LTBI) treatment, compared to the standard 9-month isoniazid regimen. While 3HP has shown comparable efficacy with higher completion rates, its effectiveness in routine healthcare settings needs further assessment.
Paper Details　
Original Abstract of the Article :
Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in rout...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/28575208

データ提供：米国国立医学図書館（NLM）

High Treatment Completion Rates for Latent Tuberculosis Infection

This study examines the completion rates of a new treatment regimen for latent tuberculosis infection (LTBI), a condition in which the bacteria that cause tuberculosis are dormant in the body. The authors assessed the effectiveness of a 12-week regimen of directly observed isoniazid and rifapentine (3HP) compared to a 9-month regimen of isoniazid in routine healthcare settings.

Improved Completion Rates for LTBI Treatment

The study found that the 3HP regimen had significantly higher completion rates than the standard 9-month isoniazid regimen. These findings suggest that the 3HP regimen may improve treatment adherence and ultimately lead to better outcomes for patients with LTBI.

Improving Tuberculosis Treatment

This research provides evidence for the effectiveness of a new treatment regimen for latent tuberculosis infection. The increased completion rates observed with the 3HP regimen have significant implications for public health, as it can help to reduce the spread of tuberculosis.

Dr. Camel's Conclusion

It's like finding a precious oasis in the midst of the desert. This new treatment regimen for latent tuberculosis infection offers a more effective and convenient approach to treatment. By improving treatment adherence, this regimen can help to curb the spread of tuberculosis and improve patient outcomes.

Date :
  1. Date Completed 2019-07-02
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

28575208

DOI: Digital Object Identifier

NIHMS880952

Related Literature

Article Analysis
・Side Effects of rifapentine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.